

ADIPS - Novo Nordisk Research Grants 2017

The ADIPS - Novo Nordisk Grants for: Clinical Research \$6000 Scientific Research \$6000 Education Research \$6000

These grants are encouragement awards in the field of Diabetes in Pregnancy. They are funded with equal contributions from ADIPS and Novo Nordisk Pharmaceuticals Pty Ltd. They may be suitable for pilot studies but are not intended to fund large scale projects or salaries. Priority will be given to new investigators, novel submissions, and proposals which are not additional studies within existing funded projects. It is expected that projects will be completed within one year and that the successful applicants should undertake to present their findings at the ADIPS Annual Scientific Meeting in the following 1–2 years.

The applicants must be financial members of ADIPS. For the membership application form go to the ADIPS website at: www.adips.org

Submissions should be of no more than 2 pages. They must indicate:

Title	Grant Category
Investigators	Project details
Institution and contact	Significance of the project

In addition, the following questions need to be answered:

- Is this proposal a component or sub-study of a larger project with existing funding or where funding from another body has been sought?
- Name of the administering body.

Grant applications to:

Suzie Neylon, ADIPS Executive Officer at sneylon@adips.org
T (02) 8247 6298 F (02) 9251 8174

Enquiries to: Suzie Neylon, Executive Officer E: sneylon@adips.org

The successful applicants will be announced during the presentation of awards session at the conclusion of the ASM in Canberra.

The 2017 ADIPS-Novo Nordisk Research Grants are generously co-sponsored by Novo Nordisk Pharmaceuticals Pty Ltd.

CLOSING DATE
5pm Monday
4th September 2017



© Registered trademark of Novo Nordisk A/S AU/NING/0616/0065

The Grant Review Committee reserves the right to not award a grant within a category if there are no applications of adequate standard and may, in such circumstances, award 3 grants in another category. The Committee's decision is final and no negotiation will be entered into.

changing
diabetes®

